Blog
RSS FeedPosted by Michael Wonder on 13 Nov 2023
Informing real-time decisions with post-market drug evidence
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
Posted by Michael Wonder on 28 Aug 2023
CADTH to establish industry task force on real world data for post market drug evaluations
18 August 2023 - CADTH is establishing an industry task force that will build upon the recently released guidance for reporting ...
Posted by Michael Wonder on 24 May 2023
PBAC Public Summary Document - May 2023
24 May 2023 - The Public Summary Document of the PBAC's consideration of the interim report of the post-market review of ...
Posted by Michael Wonder on 20 Jan 2023
Consultation on the revised PBS post-market review framework – publication of responses
20 January 2023 - Consultation on a revised draft of the PBS post-market review framework was open from 20 October ...
Posted by Michael Wonder on 22 Dec 2022
Final report for the post-market review of medicines for smoking cessation and review outcomes
22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...
Posted by Michael Wonder on 29 Nov 2022
External consultation on the draft revised post-market review framework (deadline extension)
29 November 2022 - The Department of Health and Aged Care has received a request to extend the consultation period on ...
Posted by Michael Wonder on 20 Oct 2022
Consultation on the revised PBS post-market review framework
20 October 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised ...
Posted by Michael Wonder on 01 Sep 2022
CADTH launches post-market drug evaluation program
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
Posted by Michael Wonder on 09 Aug 2022
Network collaborators announced for CADTH’s post-market drug evaluation network
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
Posted by Michael Wonder on 16 Jun 2022
Core network partners announced for CADTH’s post-market drug evaluation network
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...
Posted by Michael Wonder on 05 Feb 2022
CADTH establishes new post-market drug evaluation program
4 February 2022 - CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in ...
Posted by Michael Wonder on 03 Feb 2022
Stakeholder consultation forum: post-market review of opiate dependence treatment program medicines
3 February 2022 - A stakeholder consultation forum for the post-market review of opiate dependence treatment program medicines will be ...
Posted by Michael Wonder on 12 Nov 2021
Progress update: post-market review of medicines for smoking cessation
12 November 2021 - In June 2021, the Drug Utilisation Sub-Committee and the Economics Sub-Committee of the PBAC considered the report ...
Posted by Michael Wonder on 17 Aug 2021
Final terms of reference and public consultation to the post-market review of opiate dependence treatment program medicines
17 August 2021 - The public consultation process for the post-market review of opiate dependence treatment program medicines is now ...
Posted by Michael Wonder on 05 Jul 2021
Medical devices reforms: enhancements to post-market monitoring
5 July 2021 - This project has been established to enhance the adverse event reporting processes. ...